Search Results

You are looking at 1 - 10 of 15 items for :

  • "cutaneous T-cell lymphoma" x
Clear All
Full access

Matthew Ulrickson, Fred Okuku, Victoria Walusansa, Oliver Press, Sam Kalungi, David Wu, Fred Kambugu, Corey Casper and Jackson Orem

Cutaneous T-cell lymphomas (CTCL) constitute 2% of all non-Hodgkin’s lymphoma diagnoses in the United States. The most common subtypes are mycosis fungoides (MF) and its leukemic presentation, Sézary syndrome (SS). 1 CTCLs were noted to occur

Full access

Steven M. Horwitz, Elise A. Olsen, Madeleine Duvic, Pierliugi Porcu and Youn H. Kim

of any products discussed in the article or their competitors. References 1. Criscione VD Weinstock MA . Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002 . Arch Dermatol 2007 ; 143 : 854 – 859 . 2

Full access

Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar and Youn H. Kim

grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc. Overview Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin’s lymphomas that primarily present in the skin but can involve lymph

Full access

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, John C. Byrd, Myron S. Czuczman, Luis Fayad, Andres Forero, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Youn H. Kim, Ann S. LaCasce, Tariq I. Mughal, Auyporn Nademanee, Pierluigi Porcu, Oliver Press, Leonard Prosnitz, Nashitha Reddy, Mitchell R. Smith, Lubomir Sokol, Lode Swinnen, Julie M. Vose, William G. Wierda, Joachim Yahalom and Furhan Yunus

cutaneous T-cell lymphomas (CTCLs). 22 The new categories include primary cutaneous gamma-delta T-cell lymphoma, primary cutaneous aggressive epidermotropic CD9+ cytotoxic T-cell lymphoma, and primary cutaneous small/medium CD4+ T-cell lymphoma. ALCL, ALK

Full access

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom and Nadeem Zafar

% of all primary cutaneous lymphomas. 359 , 360 In the United States, the SEER data from the NCI indicated that the incidence of cutaneous T-cell lymphomas accounted for 71%, whereas CBCLs accounted for 29% from 2001 to 2005. 361 The new WHO

Full access

Andy I. Chen and Ranjana H. Advani

Edited by Kerrin G. Robinson

refractory cutaneous T-cell lymphoma . Blood 2007 ; 109 : 4655 – 4662 . 27. d'Amore F Radford J Jerkeman M . Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non

Full access

Constantine S. Mitsiades and Kenneth C. Anderson

deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report . Blood 2001 ; 98 : 2865 - 2868 . 99. Duvic M Talpur R Ni X . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid

Full access

Vose Julie M. 22 MD Yahalom Joachim 1 MD Zafar Nadeem 23 MD Dwyer Mary A. 24 MS Naganuma Maoko 24 MSc 03 2013 11 11 3 3 257 257 273 273 jnccn0110257 10.6004/jnccn.2013.0037 Cutaneous T-Cell Lymphoma in Sub

Full access

Sari M. Fien and Allan R. Oseroff

-infection . Eur J Med Res 2002 ; 7 : 477 – 479 . 60. Leman JA Dick DC Morton CA . Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma . Clin Exp Dermatol 2002 ; 27 : 516 – 518 . 61. Wolf P Fink-Puches R

Full access

. The epigenetic modulator romidepsin, a histone deacetylase inhibitor, also received recent FDA-approval for the treatment of cutaneous T-cell lymphoma. Most newer agents in the pipeline for treating hematologic malignancies are generally not the